Target-oriented therapy: Emerging drugs for atopic dermatitis

  title={Target-oriented therapy: Emerging drugs for atopic dermatitis},
  author={Felix Lauffer and Johannes Ring},
  journal={Expert Opinion on Emerging Drugs},
  pages={81 - 89}
  • F. Lauffer, J. Ring
  • Published 2 January 2016
  • Medicine, Biology
  • Expert Opinion on Emerging Drugs
ABSTRACT Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease with a life-time prevalence of 10 – 20% in western countries. Patients suffer from stigmatizing eczematous skin lesions, persisting itch and sleep disorders. Starting usually in early childhood the course of AD is heterogeneous. While most frequently AD disappears before adolescence, about 30% of patients show a chronic persisting course. There is an urgent need for new therapeutic options as until now… 
Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy
Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor α subunit that is able to block the signaling of bothIL-4 and IL-13 and achieve rapid and significant improvements in adults with moderate-to-severe AD.
Atopic dermatitis : emerging therapies Two identically designed phase III clinical trials
Novel topical and systemic therapies for the safe and effective long-term management of AD are greatly needed as well as novel early life approaches to preventing the disease onset.
Dupilumab for the Treatment of Atopic Dermatitis.
Systemic Treatment of Adult Atopic Dermatitis: A Review
This review focuses on the use of systemic treatments in adult AD patients analyzing published literature and indicates that standardized international guidelines are lacking, and the treatment approach widely differs among diverse countries.
Current and emerging topical therapies for atopic dermatitis.
Molecular signatures order the potency of topically applied anti‐inflammatory drugs in patients with atopic dermatitis
The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus
The etiopathogenesis of the disease is summarized and a rationale for choosing the novel targeted therapy that will be available in the future is provided.
The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis
This review summarizes the etiopathogenesis of AD and provides the rationale for selecting a novel targeted therapy, Dupilumab, which has recently been developed for AD treatment.
The IL-4, IL-13 and IL-31 pathways in atopic dermatitis
The IL-4, IL-13, and IL-31 inflammatory pathways have been identified as hallmark features in the pathogenesis of the disease, contributing uniquely and synergistically to immune and barrier abnormalities as well as the key symptoms, such as pruritis.
Pathophysiology, Diagnosis, and Management of Infections in Atopic Dermatitis
Assessment of recent changes in the understanding of pathophysiology, diagnosis, and management of infections in Atopic dermatitis finds that more targeted therapies and skin probiotics may address inflammation and S. aureus in the prevention of infection in AD.


Guidelines for treatment of atopic eczema (atopic dermatitis) Part II
The existing evidence for treatment of atopic eczema (atopic dermatitis, AE) is evaluated using the national standard Appraisal of Guidelines Research and Evaluation. The consensus process consisted
Immunology of atopic eczema: overcoming the Th1/Th2 paradigm
Current understanding of immune as well as barrier abnormalities into the pathogenesis mosaic of AE are pieces together.
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity, and side-effect profiles were not dose-limiting.
Treatment of severe refractory adult atopic dermatitis with ustekinumab
A 21-year-old Caucasian woman presented in March 2003 with a longstanding history of atopic dermatitis (AD) in addition to allergic contact dermatitis that emerged in response to paraphenylenediamine and had been diagnosed one year earlier.
Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab.
An improvement in AD was observed during the treatment period, with aggravation during follow-up, and further research is needed, based on the principle of reducing IgE levels in order to improve clinical symptoms, using a combination anti-IgE treatment approach, adjusted according to IgE Levels.
Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy
It is suggested that CyA treatment may improve the long‐term outcome of atopic dermatitis, although most patients initially relapsed a few weeks after CyA was stopped, although all disease parameters showed improvement when these patients were seen 1 year after the study.
Characterization of different courses of atopic dermatitis in adolescent and adult patients
The aim of this study was to classify different courses of AD and to correlate these with specific risk factors for severe variants of AD.
A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.
Gene ontologic analyses comparing baseline with samples during treatment revealed alterations in immune response pathways, especially those related to cyclic adenosine monophosphate–mediated signaling, which support further development of apremilast for treatment of atopic dermatitis.